0001567619-19-012607.txt : 20190603 0001567619-19-012607.hdr.sgml : 20190603 20190603173919 ACCESSION NUMBER: 0001567619-19-012607 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190530 FILED AS OF DATE: 20190603 DATE AS OF CHANGE: 20190603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DIVIS GREG J CENTRAL INDEX KEY: 0001410677 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37977 FILM NUMBER: 19874497 MAIL ADDRESS: STREET 1: 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AVADEL PHARMACEUTICALS PLC CENTRAL INDEX KEY: 0001012477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK STREET 2: BALLYCOOLIN CITY: DUBLIN STATE: L2 ZIP: 15 BUSINESS PHONE: 636-449-1830 MAIL ADDRESS: STREET 1: 16640 CHESTERFIELD GROVE ROAD STREET 2: SUITE 200 CITY: CHESTERFIELD STATE: MO ZIP: 63005 FORMER COMPANY: FORMER CONFORMED NAME: FLAMEL TECHNOLOGIES SA DATE OF NAME CHANGE: 19960422 4 1 doc1.xml FORM 4 X0306 4 2019-05-30 0 0001012477 AVADEL PHARMACEUTICALS PLC AVDL 0001410677 DIVIS GREG J C/O AVADEL PHARMACEUTICALS PLC BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK DUBLIN L2 15 IRELAND 0 1 0 0 Chief Executive Officer ADSs 67100 D Stock Option (right to buy) 10.4 2026-12-14 ADSs 150000 150000 D Stock Option (right to buy) 8.95 2027-12-12 ADSs 100000 100000 D Stock Option (right to buy) 7.06 2028-03-22 ADSs 50000 50000 D Stock Option (right to buy) 1.85 2029-03-07 ADSs 100000 100000 D Stock Option (right to buy) 1.71 2019-05-30 4 A 0 400000 0.00 A 2029-05-30 ADSs 400000 400000 D The issuer's "ADSs" are American Depositary Shares, with each ADS representing one ordinary share, nominal value $0.01 per share, of the issuer; ADSs may be represented by American Depositary Receipts. Includes (a) 22,500 restricted shares granted under the issuer's Omnibus Incentive Compensation Plan on 12/12/2017, under which 15,000 ADSs will vest and be issued on the second anniversary of the grant date and the remaining 7,500 ADSs will vest and be issued on the third anniversary of the grant date (with vesting of these restricted shares subject to the reporting person remaining in continuous service until the applicable anniversary of the date of grant); and (b) 18,000 restricted ADSs granted under the issuer's Omnibus Incentive Compensation Plan on 3/7/2019, of which 12,000 and 6,000 ADSs will vest and be issued to the reporting person on the 2nd anniversary and 3rd anniversary, respectively, of the grant date (with such vesting subject to the reporting person remaining in continuous service until the applicable anniversary). Options become exercisable as to 37,500 ADSs on each of the first four anniversaries after the 12/14/2016 grant date. Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 12/12/2017 grant date. Options become exercisable as to 12,500 ADSs on each of the first four anniversaries after the 3/22/2018 grant date. Options become exercisable as to 25,000 ADSs on each of the first four anniversaries after the 3/7/2019 grant date. Options become exercisable as to 100,000 ADSs on each of the first four anniversaries after the 5/30/2019 grant date. /s/ Phillandas T. Thompson as attorney in fact for Greg J. Divis 2019-06-03